Arecor Therapeutics PLC SPECIALTY HOSPITAL FORMULATION COLLABORATION (9078F)

TIDMAREC

RNS Number : 9078F

Arecor Therapeutics PLC

10 November 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world's largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs .

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat(TM), to develop a differentiated, stable, liquid drug product, for intravenous administration, that is Ready-to-Use ("RTU"). The new liquid formulation of the product supports safe medication practices and operational efficiency by eliminating the need for reconstitution. The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.

This collaboration adds to Arecor's growing portfolio of pre-license technology partnerships which, subject to licensing, typically include both potential milestone and royalty payments and could offer significant future recurring revenue upside potential for the Group.

Sarah Howell, Chief Executive Officer of Arecor, said: "This collaboration further demonstrates the strength of our proprietary technology platform, Arestat(TM), and its potential in the development of Ready-to-Use medicines. This is a field in which Arecor is building a considerable portfolio of potential specialty hospital products, as well as bringing our technology and experience to further our partners' products. Our expertise in formulating complex medicines, when combined with our partner's global network and specific local knowledge of providing access to the major markets worldwide, will be key to advancing these fast, safe and effective treatments for patients."

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: +44 (0) 20 3709 5700 
  Gray                                       Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFFFLILFLAIIF

(END) Dow Jones Newswires

November 10, 2022 02:00 ET (07:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024